Helping the brain's immune cells clear Alzheimer's with small RNA medicines
Targeting brain myeloid cells with siRNA-lipid conjugates for treatment of Alzheimer's disease
A new delivery method will get small RNA medicines into brain immune cells for people with Alzheimer's disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-11232338 on NIH RePORTER |
What this research studies
The team is working on a method that could one day let doctors deliver tiny RNA medicines into the fluid around your brain so they reach the brain's immune cells (microglia and macrophages). They attach the RNA to a fatty carrier that binds albumin, which travels along spaces around blood vessels and can carry the medicine deeper into the brain than current approaches. In lab and animal tests they will check whether this improves uptake by brain immune cells and reduces Alzheimer's-related markers like amyloid beta. This work is primarily preclinical now, focusing on lab and animal experiments rather than directly treating patients.
Who could benefit from this research
Good fit: Patients with Alzheimer's disease—particularly those in earlier stages or with genetic risk linked to myeloid genes like CD33—would be the most likely candidates for future trials based on this work.
Not a fit: People without Alzheimer's, those with very advanced disease, or individuals who cannot undergo procedures to access cerebrospinal fluid are unlikely to benefit from this preclinical work in the near term.
Why it matters
Potential benefit: If successful, this approach could help lower harmful amyloid buildup and slow Alzheimer's progression by improving delivery of gene-targeting drugs to brain immune cells.
How similar studies have performed: Other oligonucleotide therapies have succeeded for some neurological diseases, but delivering siRNA specifically to microglia is a newer approach that remains mostly at the preclinical stage.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Lippmann, Ethan — Vanderbilt University
- Study coordinator: Lippmann, Ethan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.